Health Care • Ophthalmic Goods
$20.40 ▲ +0.00
(0.00%)
MKT CAP: $7.29B • VOL: 3.45M
52W L $14 52W H $21
BLCO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.10B | $4.79B | $4.15B |
| YoY Revenue Growth % | +6.5% | +15.6% | — |
| Gross Profit | $2.24B | $2.11B | $1.82B |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $113.0M | $162.0M | $130.0M |
| Operating Margin % | 2.2% | 3.4% | 3.1% |
| Net Income (GAAP) | -$360.0M | -$317.0M | -$260.0M |
| EBITDA (Normalized) | $392.2M | $394.8M | $279.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $283.0M | $232.0M | -$17.0M |
| Capital Expenditures (CapEx) | $349.0M | $291.0M | $186.6M |
| Free Cash Flow (FCF) | -$66.0M | -$59.0M | -$203.6M |
| FCF Margin % | -1.3% | -1.2% | -4.9% |
| Return on Invested Capital (ROIC %) | 0.8% | 1.2% | 3.4% |
| Cash & Short-Term Equivalents | $383.0M | $305.0M | $547.3M |
| Total Debt (Short + Long Term) | $5.02B | $4.74B | $1.16B |
| Total Stockholders' Equity | $6.45B | $6.47B | $2.39B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BLCO.